Polycythemia Vera: all 238 studies
Page 2 of 3. Open to participants first (57), then studies with results posted, then the rest; newest registration first within each.
- A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological MalignanciesCompletedNCT01384513Phase 2Results posted
- Efficacy and Safety of Simtuzumab in Adults With Primary, Post Polycythemia Vera or Post Essential Thrombocythemia MyelofibrosisCompletedNCT01369498Phase 2Results posted
- Ruxolitinib (INCB018424) in Participants With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis (PPV-MF)CompletedNCT01348490Phase 2Results posted
- Anti-TGF-beta Therapy in Patients With MyelofibrosisTerminatedNCT01291784Phase 1Results posted
- Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET)CompletedNCT01259856Phase 3Results posted
- Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial)CompletedNCT01243944Phase 3Results posted
- Study of SB939 in Subjects With MyelofibrosisCompletedNCT01200498Phase 2Results posted
- Trial of Erlotinib in Patients With JAK-2 V617F Positive Polycythemia VeraTerminatedNCT01038856Phase 2Results posted
- COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I TrialCompletedNCT00952289Phase 3Results posted
- Pomalidomide for Myelofibrosis PatientsCompletedNCT00946270Phase 2Results posted
- Controlled Myelofibrosis Study With Oral Janus-associated Kinase (JAK) Inhibitor Treatment-II: The COMFORT-II TrialCompletedNCT00934544Phase 3Results posted
- A Study to Evaluate Safety and Efficacy of Panobinostat in Participants With Primary MyelofibrosisTerminatedNCT00931762Phase 2Results posted
- Phase II Study of GIVINOSTAT (ITF2357) in Combination With Hydroxyurea in Polycythemia VeraCompletedNCT00928707Phase 2Results posted
- Study to Assess the Safety of AZD1480 in Patients With Myeloproliferative DiseasesCompletedNCT00910728Phase 1Results posted
- CC-4047 in Treating Patients With MyelofibrosisCompletedNCT00669578Phase 1/2Results posted
- Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other DisordersActive, not recruitingNCT00544115Phase 2Results posted
- Dasatinib in Polycythemia VeraTerminatedNCT00538980Phase 2Results posted
- Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia MyelofibrosisCompletedNCT00509899Phase 1/2Results posted
- Cyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic SyndromeCompletedNCT00445744Not applicableResults posted
- Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative DisordersCompletedNCT00397813Phase 2Results posted
- 3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous LeukemiaCompletedNCT00381550Phase 2Results posted
- Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)CompletedNCT00255346Phase 2Results posted
- Lenalidomide and Prednisone in Treating Patients With MyelofibrosisCompletedNCT00227591Phase 2Results posted
- Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without CancerCompletedNCT00112593Not applicableResults posted
- Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic CancerCompletedNCT00089011Phase 2Results posted
- Therapy of HES, PV, Atypical Chronic Myelocytic Leukemia (CML) or Chronic Myelomonocytic Leukemia (CMML), and Mastocytosis With Imatinib MesylateCompletedNCT00038675Not applicableResults posted
- A Study of Real-world Use and Effectiveness of Cytoreductive Strategies for the Treatment of Second-line Polycythemia Vera in FranceCompletedNCT07839858
- A Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV)Active, not recruitingNCT06985147Phase 2
- Unraveling the Role of Extracellular Vesicles-driven Senescence in Myeloproliferative NeoplasmsActive, not recruitingNCT06798805
- LOW-PV ContinuationCompletedNCT06752941
- Ultrasound Examination for Spleen Volume Evaluation in Myeloproliferative NeoplasmsCompletedNCT06371573
- Efficacy and Safety of Ropeginterferon Alfa 2b (P1101) for Patients With Polycythemia VeraWithdrawnNCT06290765Phase 4
- Clinical and Laboratory Characteristics of Polycythemia VeraCompletedNCT06134102
- Ruxolitinib Adherence in Myelofibrosis and Polycythemia VeraCompletedNCT06078319
- Study to Evaluate the Long-term Safety of Rusfertide (PTG-300) in Subjects With Polycythemia VeraActive, not recruitingNCT06033586Phase 3
- A Study to Evaluate P1101 in Japanese PV PatientsCompletedNCT06002490Phase 3
- Evaluation of HU-resistance in Adult Patients With Polycythemia Vera Who Meet PV-AIM PredictorsTerminatedNCT05853458Phase 4
- A Prospective, Non-interventional Study of JAKAVI® (Ruxolitinib) Treatment in Patients With Polycythemia VeraCompletedNCT05853445
- Changes in QoL and Symptoms in Patients With Polycythemia Vera Receiving Ruxo in a Routine Clinical PracticeStatus unknownNCT05566535
- Study to Identify and Describe Predictive Factors for Thromboembolic Events in Patients With High-risk Polycythemia VeraActive, not recruitingNCT05548062
- Study to Assess SLN124 in Patients With Polycythemia VeraActive, not recruitingNCT05499013Phase 1/2
- A Study to Access Efficacy and Safety of P1101 in Chinese PV Patients Who Are Intolerant or Resistance to HUActive, not recruitingNCT05485948Phase 2
- A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PVActive, not recruitingNCT05481151Phase 3
- Ruxolitinib for Polycythemia Vera in Patients Resistant to or Intolerant of Hydroxyurea.CompletedNCT05421104
- MAP to Provide Access to Ruxolitinib, for Patients With Polycythemia VeraNo longer availableNCT05269771
- A Study to Evaluate Sapablursen (Formerly ISIS 702843, IONIS-TMPRSS6-LRx) in Patients With Polycythemia VeraCompletedNCT05143957Phase 2
- Safety Evaluation Study for Patients With Polycythemia VeraStatus unknownNCT05074550Phase 1
- A Prospective, Two-arm, Non-interventional Study of JAKAVI® (Ruxolitinib) in Patients With MyelofibrosisCompletedNCT05044026
- A Study of LNK01002 in Patients With Primary or Secondary Myelofibrosis,Polycythemia Vera or Acute Myeloid LeukemiaWithdrawnNCT04896112Phase 1
- PTG-300 in Patients With Polycythemia Vera and Elevated HematocritCompletedNCT04767802Phase 2
- Elotuzumab for the Treatment of JAK2-Mutated MyelofibrosisActive, not recruitingNCT04517851Phase 2
- An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post ET-MF) Who Have a Suboptimal Response to RuxolitinibStatus unknownNCT04485260Phase 1/2
- Study of Select Combinations in Adults With MyelofibrosisWithdrawnNCT04283526Phase 1
- IMG-7289 in Patients With Essential Thrombocythemia (ET) or Polycythemia Vera (PV)Active, not recruitingNCT04262141Phase 2
- Assessing Feasibility of Thromboprophylaxis With Apixaban in JAK2-positive Myeloproliferative Neoplasm PatientsCompletedNCT04243122Phase 2
- Jaktinib for the Treatment of Ruxolitinib Intolerance of MyelofibrosisCompletedNCT04217993Phase 2
- Hepcidin Mimetic in Patients With Polycythemia Vera (REVIVE)CompletedNCT04057040Phase 2
- PAT-1251 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis MyelofibrosisWithdrawnNCT04054245Phase 2
- Dual Vaccine Trial in Myeloproliferative NeoplasmsCompletedNCT04051307Phase 1/2
- CPAP in Treating Obstructive Sleep Apnea in Patients With Polycythemia Vera or Essential ThrombocythemiaTerminatedNCT03972943Early Phase 1
- Assess the Safety, Tolerability Oral PU-H71 in Subjects Taking RuxolitinibTerminatedNCT03935555Phase 1
- The NUTRIENT Trial (NUTRitional Intervention Among myEloproliferative Neoplasms): Feasibility PhaseCompletedNCT03907436Not applicable
- MPN-RC 118 AVID200 in MyelofibrosisCompletedNCT03895112Phase 1
- Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid LeukemiaActive, not recruitingNCT03862157Phase 1/2
- Secondary Cancers in Myeloproliferative Neoplasms (MPN-K Study)CompletedNCT03745378
- KRT-232 Compared to Ruxolitinib in Patients With Phlebotomy-Dependent Polycythemia VeraStatus unknownNCT03669965Phase 2
- Evaluation of Ruxolitinib in Combination With PU-H71 for Treatment of MyelofibrosisTerminatedNCT03373877Phase 1
- 18F-FLT (PET/CT) in Pediatrics With Myeloproliferative NeoplasmsTerminatedNCT03121599Not applicable
- The Benefit/Risk Profile of AOP2014 in Low-risk Patients With PVCompletedNCT03003325Phase 2
- Treatment of Polycythaemia Vera and Essential Thrombocythaemia: Influence on the Clot StructureCompletedNCT02912884
- Drug Observance and Side Effects of Cytoreductive Drugs in PV and ET PatientsCompletedNCT02893410
- Durvalumab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia MyelofibrosisWithdrawnNCT02871323Phase 1
- Endoplasmic Reticulum Stress and Resistance to Treatments in Ph-negative Myeloproliferative NeoplasmsCompletedNCT02823184
- Incidence of Iron Deficiency in Polycythemia Vera (PV) and Association With Disease FeaturesStatus unknownNCT02809274
- Siltuximab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia MyelofibrosisWithdrawnNCT02805868Early Phase 1
- Cell Cycle Regulatory Gene Study in Patients With Myeloproliferative DisordersWithdrawnNCT02663648
- A Phase II Non-Controlled, Open-Label, Efficacy, Safety, Pharmacokinetic, and Pharmacodynamic Study of Pacritinib in MyelofibrosisWithdrawnNCT02584777Phase 2
- The Ruxo-BEAT Trial in Patients With High-risk Polycythemia Vera or High-risk Essential ThrombocythemiaActive, not recruitingNCT02577926Phase 2
- Study to Assess the Self-administration of AOP2014 Using a Pen, Developed for the Treatment of Polycythemia Vera PatientsCompletedNCT02523638Phase 3
- TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to HydroxyureaCompletedNCT02493530Phase 1
- Open Label Study of Single Agent Oral RG7388 in Patients With Polycythemia Vera and Essential ThrombocythemiaCompletedNCT02407080Phase 1
- CINC424A2X01B Rollover ProtocolActive, not recruitingNCT02386800Phase 4
- Sympathicomimetic Agonist in Patients With Myeloproliferative Neoplasms With JAK2-mutationCompletedNCT02311569Phase 2
- Prospective Observational Study Of Patients With Polycythemia Vera In US Clinical Practices (REVEAL)CompletedNCT02252159
- AOP2014 vs. BAT in Patients With Polycythemia Vera Who Previously Participated in the PROUD-PV Study.CompletedNCT02218047Phase 3
- Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid MalignanciesCompletedNCT02129101Phase 1
- Safety and Efficacy of Momelotinib in Subjects With Polycythemia Vera or Essential ThrombocythemiaTerminatedNCT01998828Phase 2
- Tissue Banking Study - Polycythemia Vera or Essential Thrombocythemia (PV & ET) PatientsCompletedNCT01970930
- Pegylated Interferon Alpha-2b Versus Hydroxyurea in Polycythemia VeraCompletedNCT01949805Phase 3
- Screening for Asymptomatic Portal Vein Thrombosis and Portal Hypertension in Patients With Philadelphia Negative Myeloproliferative NeoplasmsCompletedNCT01816256Not applicable
- Myeloproliferative Neoplasms and Bone StructureStatus unknownNCT01816022
- Ruxolitinib Phosphate and Azacytidine in Treating Patients With Myelofibrosis or Myelodysplastic Syndrome/Myeloproliferative NeoplasmCompletedNCT01787487Phase 2
- Phase 2 Study in Japanese Patients With Intermediate-2 or High Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis With SplenomegalyCompletedNCT01692366Phase 2
- Large-scale Trial Testing the Intensity of CYTOreductive Therapy in Polycythemia Vera (PV)TerminatedNCT01645124Phase 3
- An Open Label Study of Itacitinib Administered Orally in Patients With MyelofibrosisCompletedNCT01633372Phase 2
- Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell TransplantCompletedNCT01588015Phase 1
- Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative NeoplasmsCompletedNCT01520220Phase 1
- Panobinostat and Ruxolitinib in Primary Myelofibrosis, Post-polycythemia Vera-myelofibrosis or Post-essential Thrombocythemia-myelofibrosisCompletedNCT01433445Phase 1
- Safety Study Evaluating Twice-Daily Administration of Momelotinib in Primary Myelofibrosis or Post-Polycythemia Vera or Post-Essential Thrombocythemia MyelofibrosisCompletedNCT01423058Phase 1/2
- Study With SAR302503 in Patients With Polycythemia Vera or Essential ThrombocythemiaCompletedNCT01420783Phase 2